Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's LG Life Sciences Signs Deal With China's Double-Crane Covering DPP-4 Inhibitor Gemigliptin

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes

You may also be interested in...



Korea’s Dong-A Out-licenses DPP-4 To India’s Alkem Laboratories

Staggering under a tightened regulatory grip and price cuts at home, Korea’s Dong-A is trying to capture growth momentum from overseas.

Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?

After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.

Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?

After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.

Related Content

UsernamePublicRestriction

Register

SC073032

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel